A history of cancer chemotherapy

Cancer Research

Volumn 68, Issue 21, 2008, Pages 8643-8653

  DeVita Jr , Vincent T ^a   Chu, Edward ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BEVACIZUMAB; BLEOMYCIN; CETUXIMAB; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ESTROGEN; FLUOROURACIL; FOLIC ACID ANTAGONIST; IMATINIB; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; PENICILLIN G; PHOSPHOTRANSFERASE INHIBITOR; PREDNISONE; PROCARBAZINE; RITUXIMAB; TAXANE DERIVATIVE; THIOTEPA; TIOGUANINE; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ACUTE LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BLADDER CANCER; BREAST CANCER; BURKITT LYMPHOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CHORIOCARCINOMA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DEVELOPMENT; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; EMBRYONAL RHABDOMYOSARCOMA; ESOPHAGUS CANCER; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; GOUT; HEAD AND NECK CANCER; HEALTH CARE ORGANIZATION; HERPES; HISTORY OF MEDICINE; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LAW; LUNG NON SMALL CELL CANCER; LYMPHATIC SYSTEM TUMOR; NASOPHARYNX CANCER; NEOPLASM; NEPHROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STOMACH CANCER; TESTIS CANCER; UNSPECIFIED SIDE EFFECT; WAR;

ANIMALS; ANTINEOPLASTIC AGENTS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NEOPLASMS;

EID: 55349136976     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6611     Document Type: Review

References (101)

1. Brested JH. The Edwin Smith surgical papyrus. Translated for The New York Historical Society. Chicago (IL): University of Chicago Press; 1930.
2. Papac RJ. Origins ofsf cancer therapy. Yale J Biol Med 2001;74:391-8.
3. DeVita VT. The evolution of therapeutic research in cancer. N Engl J Med 1978;298:907-10.
4. Osler W. The principles and practice of medicine. New York: D. Appleton and Company; 1893. p. 708.
5. Goldin A, Schepartz SA, Venditti JM, DeVita VT. Historical development and current strategy of the National Cancer Institute Drug Development Program. In: Busch H, DeVita VT, editors. Methods in cancer research, V16(A). New York: Academic Press; 1979. p. 165-245.
6. Hirschberg E. Patterns of response of animal tumors to anticancer agents. Cancer Res 1963;23:521-980.
7. Shear MJ, Hartwell JL, Peters VB, et al. Some aspects of a joint institutional research program on chemotherapy of cancer: current laboratory and clinical experiments with bacterial polysaccharide and with synthetic organic compounds. In: Moulton FR, editor. Approaches to tumor chemotherapy. Washington (DC): American Association for the Advancement of Science; 1947. p. 236-84.
8. Zubrod CG, Schepartz S, Leiter J, Endicott JM, Carrese LM, Baker CG. The chemotherapy program of the National Cancer Institute: History, analysis, and plans. Cancer Chemother. Rep 1966;50:349-540.
9. Zubrod CG, Schepartz SA, Carter SK. Historical background for the National Cancer Institute's drug development thrust. Natl Cancer Inst Monogr 1977;45:7-11.
10. Boyland E. Experiments on the chemotherapy of cancer. I. The effects of certain antibacterial substances and related compounds. Biochem J 1938;32:1207-13.
11. Yoshida T. The Yoshida sarcoma, an ascites tumor. Gann 1949;40:1-20.
12. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896;2:104-7;162-165.
13. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effects of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
14. Marshall EKJR. Historical perspectives in chemotherapy. In: Golding A, Hawking IF, editors. Advances in chemotherapy, vol. 1. New York: Academic Press; 1964. p. 1-8.
15. Krumbhaar EB, Krumbhaar HD. The blood and bone marrow in yellow gas (mustard gas) poisoning. Changes produced in bone marrow in fatal cases. J Med Res 1919;40:497-508.
16. Gilman A. Symposium on advances in pharmacology resulting from war research: therapeutic applications of chemical warfare agents. Fed Proc 1946;5:285-292.
17. Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT. Nitrogen mustard therapy: use of methyl-bis (β-chloroethyl) amine hydrochloride and tris (β-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia, and certain allied and miscellaneous disorders. JAMA 1946;132:126-32.
18. Gilman A, Philips FS. The biological actions and therapeutic applications of the β-chloroethylamines and sulfides. Science 1946;103:409-15.
19. Karnofsky DA, Burchenal JH, Ormsler RA, Corman I, Rhoads CP. Experimental observations on the use of nitrogen mustard in the treatment of neoplastic diseases. In: Moulton FR, editor. Approaches to tumor chemotherapy. Washington (DC): American Association for the Advancement of Science; 1947. p. 298-305.
20. Gilman A. The initial clinical trial of nitrogen mustard. Am J Surg 1963;105:574-8.
21. Farber S. Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer. Blood 1949;4:160-7.
22. Farber S, Diamond LK, Mercer RD, et al. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med 1948;238:787-93.
23. Pinkel D. Actinomycin D in childhood cancer; a preliminary report. Pediatrics 1959;23:342-7.
24. Hitchings GH, Elion GB. The chemistry and biochemistry of purine analogs. Ann NY Acad Sci 1954;60:195-9.
25. Elion GB, Singer S, Hitchings GH. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J Biol Chem 1954;208:477-88.
26. Heidelberger C, Chaudhuari NK, Danenberg P, et al. Fluorinated pyrimidines. A new class of tumor inhibitory compounds. Nature 1957;179:663-6.
27. Law LW, Dunn TB, Boyle PJ, Miller JH. Observations on the effect of a folic-acid antagonist on transplantable lymphoid leukemias in mice. J Natl Cancer Inst 1949;10:179-92.
28. Skipper HE, Schabel FM, Jr., Mellet LB, et al. Implications of biochemical, cytokinetic, pharmacologic and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 1950;54:431-50.
29. Skipper HE. Reasons for success and failure in treatment of murine leukemias with the drugs now employed in treating human leukemias. Cancer Chemother 1978;1:1-166. Ann Arbor (MI): University Microfilms International.
30. Yankee RA, DeVita VT, Perry S. The cell cycle of leukemia L1210 cells in vivo. Cancer Res 1967;27:2381-5.
31. Farber S, Schwachman H, Toch R, Downing V, Kennedy BH, Hyde J. The effect of ACTH in acute leukemia in childhood. In: Mote JR, editor. Proceedings of the First Clinical ACTH Conference. New York: McGraw-Hill-Blakiston; 1950. p. 328-30.
32. Pearson OH, Eliel LP, Rawson RW, Dobriner K, Rhoads CP. ACTH- and cortisone-induced regression of lymphoid tumors in man: a preliminary report. Cancer 1949;2:943-5.
33. Gellhorn A, Hirschberg E, editors. Investigation of diverse systems of cancer chemotherapy screening. Cancer Res Supp 1955;3:125.
34. Endicott KM. Progress report. Bethesda (MD): Cancer Chemotherapy National Service Center; 1957. p. 10.
35. Endicott KM. The chemotherapy program. J Nat Cancer Inst 1959;19:275-93.
36. Cancer Chemotherapy National Service Center specifications for screening chemical agents and natural products against animal tumors. Cancer Chemother Rep 1959;1:42-64.
37. Armitage P, Schneiderman MA. Statistical problems in a mass screening program. Ann NY Acad Sci 1958;76:896-908.
38. DeVita VT, Oliverio VT, Muggia FM, et al. The drug development and clinical trials programs of the Division of Cancer Treatment, National Cancer Institute. Cancer Clin Trials 1979;2:195-216.
39. Li MC, Hertz R, Bergenstal DM. Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. N Engl J Med 1958;259:66-74.
40. DeVita VT. Therapeutic research in the National Cancer Institute. In: Stetten D, Carrigan WT, editors. NIH: an account of research in its laboratories and clinics. New York: Academic Press; 1984. p. 500-526.
41. Hertz R, Lewis J, Lipsett MB. Five years experience with chemotherapy of metastatic trophoblastic disease in women. Am J Obstet Gynecology 1963;86:808-14.
42. Li MC, Whitmore WF, Goldbey RB, Grabstald H. Effects of combined drug therapy on metastatic cancer of the testis. JAMA 1969;174:1291.
43. Biomedical science and its administration. A study of the National Institutes of Health. Report of Wooldridge Committee to the President. Washington (DC): U.S. Government Printing Office; 1955. p. 213.
44. DeVita VT. Contrasting viewpoints on cancer drug development: the Wooldridge and Richardson reports. Cancer Treat Rep 1984;68:339-40.
45. Sessoms SM. Review of the Cancer Chemotherapy National Service Center programs; development and organization. Cancer Chemother Rep 1960;7:25-8.
46. Burchenal JH. Treatment of leukemias. Seminars in Hematology 1966;31:122.
47. Zuelzer WW. Implications of long term survival in acute stem cell leukemia of childhood treated with composite cyclic therapy. Blood 1964;24:477.
48. Frei E III, Karon M, Levin RH, et al. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 1965;26:642-56.
49. Frei E III, Freireich EJ, Gehan E et al. Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-mercaptopurine and methotrexate: from the acute leukemia group. Blood 1961;18:431-54.
50. Johnson TS, Armstrong JG, Gorman M, Burnett JP, Jr. The vinca alkaloids: a new class of oncolytic agents. Cancer Res 1963;23:1390-427.
51. Brunner KW, Young CS. A methyl hydrazine derivative in Hodgkin's disease and other malignant lymphomas. Ann Int Med 1967;66:144.
52. DeVita VT, Serpick A, Carbone PP. Preliminary clinical studies with ibenzmethyzin. Clin Pharmacol Ther 1966;7:542-6.
53. Furth J, Kahn MC. The transmission of leukemia of mice with a single cell. Am J Cancer 1937;31:276-82.
54. Skipper HE, Schabel FR, Jr., Wilcox WS. Experimental evaluation of potential anticancer agents. XII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 1964;35:1-111.
55. Freireich EJ, Karon M, Frei E III. Quadruple combination therapy (VAMP) for acute lymphocytic leukemia of childhood. Proc Am Assoc Cancer Res 1964;5:20.
56. Frei E III. Potential for eliminating leukemic cells in childhood acute leukemia. Proc Am Assoc Cancer Res 1963;5:20 (abstract).
57. Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl JMed 1962;266:905-9.
58. Hersh EM, Bodey GP, Nies BA, Freireich EJ. Causes of death in acute leukemia: a ten-year study of 414 patients from 1954-1963. JAMA 1965;193:105-9.
59. DeVita VT, Emmer M, Levine A, Jacobs B, Berard C. Pneumocystis carinii pneumonia: successful diagnosis and treatment of two patients with associated malignant processes. N Engl J Med 1969;280:287-91.
60. Holland JF. Hopes for tomorrow versus realities of today: therapy and prognosis in acute lymphocytic leukemia of childhood. Pediatrics 1970;45:191-3.
61. George P, Hernandez K, Hustu O, Borella L, Holton C, Pinkel D. A study of total therapy of acute lymphocytic leukemia in children. J Pediatr 1968;72:399-408.
62. Pinkel D, Hernandez K, Borella L, et al. Drug dose and remission duration in childhood lymphocytic leukemia. Cancer 1971;27:247-56.
63. DeVita VT, Moxley JH, Brace K, Frei E III. Intensive combination chemotherapy and X-irradiation in the treatment of Hodgkin's disease. Proc Am Assoc Cancer Res 1965;6:15.
64. Moxley JH III, DeVita VT, Brace K, Frei E III. Intensive combination chemotherapy and X-irradiation in Hodgkin's disease. Cancer Res 1967;27:1258-63.
65. DeVita VT, Serpick A. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Proc Am Assoc Cancer Res 1967;8:13.
66. DeVita VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970;73:881-95.
67. DeVita VT. Cell kinetics and the chemotherapy of cancer. Cancer Chemother Rep 1971;2:23-33.
68. DeVita VT, Denham C, Perry S. Relationship of normal CDF1 mouse leukocyte kinetics to growth characteristics of leukemia L1210. Cancer Res 1969;29:1067-71.
69. Skipper HD, Perry S. Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy. Cancer Res 1970;30:1883.
70. DeVita VT, Schein PS. The use of drugs in combination for the treatment of cancer: rationale and results. N Engl J Med 1973;288:998-1006.
71. DeVita VT, Young RC, Canellos GP. Combination versus single agent chemotherapy; a review of the basis for selection of drug treatment of cancer. Cancer 1975;35:98-110.
72. Young RC, DeVita VT. The effect of chemotherapy on the growth characteristics and cellular kinetics of leukemia L1210. Cancer Res 1970;30:1789-94.
73. DeVita VT, Canellos GP, Chabner B, Schein P, Young RC, Hubbard SM. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Results with combination chemotherapy. Lancet 1975;1:248-54.
74. DeVita VT, Canellos GP, Moxley HH III. A decade of combination chemotherapy for advanced Hodgkin's disease. Cancer 1972;30:1495-504.
75. Schabel FM. Concepts for systemic treatment of micrometastases. Cancer 1975;35:15.
76. Salmon SE. Kinetic rationale for adjuvant chemotherapy for cancer. In: Salmon SE, Jones SE, editors. Adjuvant therapy of cancer. Amsterdam: Elsevier/North Holland Biomedical Press; 1977.
77. Young RC, DeVita VT. Cell cycle characteristics of human solid tumors in vivo. Cell Tissue Kinet 1970;3:285-90.
78. Greenspan EM, Fieber M, Lesnick G, Edelman S. Response of advanced breast cancer to the combination of the anti-metabolite methotrexate and the alkylating agent thiotepa. J Mt Sinai Hosp 1963;30:246-67.
79. Canellos GP, DeVita VT, Gold GL, Chabner BA, Schein PS, Young RC. Cyclical combination chemotherapy in the treatment of advanced breast carcinoma. Proc Am Assoc Cancer Res 1974;15:148.
80. Canellos GP, DeVita VT, Gold GL, Chabner BA, Schein PS, Young RC. Cyclical combination chemotherapy in the treatment of advanced breast carcinoma. Brit Med J 1974;1:218-20.
81. Fisher B, Ravdin RG, Ausman RK, Slack NH, Moore GE, Noer RJ. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg 1968;168:337-56.
82. Fisher B, Carbone P, Economou SG, et al. L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. N Engl J Med 1975;292:110-22.
83. Bonadonna G, Brusamolino E, Valegussa P, et al. Combination chemotherapy as an adjunct treatment in operable breast cancer. N Engl J Med 1976;294:405-10.
84. Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer. In: Peto R, editor. Worldwide evidence 1985-1990, vol. 1. Oxford: Oxford University Press; 1990.
85. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294:405-10.
86. Einhorn LH, Donohue JP. Combination chemotherapy in disseminated testicular cancer: the Indiana University experience. Semin Oncol 1979;6:87-93.
87. Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Int Med 1977;87:293-8.
88. Einhorn LH. Testicular cancer as a model for a curable neoplasm: The Richard and Linda Rosenthal Foundation award lecture. Cancer Res 1981;41:3275-80.
89. DeVita VT. Le plan Nixon contre le cancer portée et limites. In: Bez G, Jasmin C, editors. Cancer, sida et société: pour une approche globale de la santé. Paris: ESF; 1993.
90. DeVita VT. A perspective on the war on cancer. Cancer J 2002;8:352-6.
91. Fischinger P, DeVita VT. Perceptions and opportunities in oncogene research. Cancer Res 1984;44:4693-6.
92. DeVita VT. The governance of science at the National Cancer Institute: a perspective of misperceptions. Cancer Res 1983;43:3969-73.
93. DeVita VT. The governance of science at the National Cancer Institute: management of resources in an era of scarcity. Cancer Research 1983;43:6106-8.
94. DeVita VT. On special initiatives, critics and the National Cancer Program. Cancer Treat Rep 1984;68:1-4.
95. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
96. Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science 2002;298:1912-34.
97. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-87.
98. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
99. Nowel PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497-501.
100. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-44.
101. Herbst RS. Therapeutic options to target angiogenesis in human malignancies. Expert Opin Emerg Drugs 2006;11:635-50.